Ibn Sina, Meghna see profits rise
The Ibn Sina Pharmaceuticals Industry Ltd said its profits shot up 28 per cent in the July-December period of the 2021-22 financial year, buoyed by its marketing drive to boost sales.
The drug maker said its earnings per share (EPS) rose to Tk 10.49 in the first-half of the current financial year ending in June, up from Tk 8.19 a year ago. The company's second quarter earnings also edged up for the same reason.
"We added new products to our basket as the overall pharmaceutical market is growing," said Md Kabir Hossain, company secretary of Ibn Sina Pharmaceuticals.
Stocks of Ibn Sina Pharmaceuticals closed at Tk 293.20 at the Dhaka Stock Exchange (DSE) yesterday, up 1.10 per cent from the previous day.
However, the company reported a decline in its net operating cash flows per share (NOCFPS) as it fell to Tk 9.74 in the six months leading up to December 2021, down 7 per cent year-on-year from Tk 10.48 .
The drug maker's consolidated net asset value per share rose 7 per cent to Tk 74.49 as of December 31, 2021, from Tk 68.69 at the end of June the same year.
Meanwhile, Meghna Petroleum said its earnings grew only 4 per cent in the first six months of the 2021-22 financial year even though it recorded a 14 per cent spike in its net profit during the October-December period.
Reza Md Riazuddin, company secretary of Meghna Petroleum, said falling bank interest rates on deposits affected its income.
The state-run petroleum marketing company registered EPS of Tk 12.74 in the July-December of the current financial year, up from Tk 12.24 a year ago, the company said in a filing with the DSE. Its earnings in the October-December period rose to Tk 6.51 from Tk 5.70 in the same period in 2020.
Stocks of Meghna Petroleum declined marginally to hit Tk 208.50 at the DSE.
NOCFPS of Meghna Petroleum increased in the first six months of the current financial year. Its net asset value per share also grew at the end of December, 2021.